Delivery Order SPE2DR25D1053-SPE2DR26FT904
- Not listed
- The Defense Logistics Agency awarded a $1,020.00 delivery order to AmerisourceBergen Drug Corp for Fulvestrant 250 mg/5 mL syringes on October 29, 2025, with completion targeted for October 30, 2025. This firm fixed-price delivery order, issued without a set-aside designation, represents a single transaction under a competitive procurement process for pharmaceutical supply. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Fulvestrant 250 mg/5 mL syringes with a ceiling value of $1,145.70. This non-set-aside, competitively awarded delivery order features firm fixed pricing and is scheduled for completion by August 8, 2025. The work will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $6,083.35 to AmerisourceBergen Drug Corp for Fulvestrant 250 mg/5 ml syringes on August 25, 2025, with completion scheduled for August 26, 2025. This competitively awarded, firm fixed-price contract utilizes no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $1,370.92 to AmerisourceBergen Drug Corp for the supply of Fulvestrant 250 mg/5 mL syringes on April 23, 2025, with an ultimate completion date of April 24, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $1 billion comprehensive pharmaceutical supply...
- The U.S. Department of Defense's Medical Supply Chain awarded a $1,530.00 delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Fulvestrant 250 mg/5 mL syringes. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 2, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a single delivery order fulfillment under AmerisourceBergen's larger indefinite delivery contract...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Fulvestrant 250 mg/5 ml syringes, a specialty medication, under a delivery order valued at $1,231.10. The contract has an ultimate completion date of December 27, 2024 and is a firm fixed-price delivery order. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $1,145.70, is for the supply of 4567954913 FULVESTRANT 250 MG/5 ML SYRING 5ML, a pharmaceutical product, with a period of performance through April 18, 2025. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which serves...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,060.00 firm-fixed-price contract is for the supply of 4567008677 - Fulvestrant 250 mg/5 ml syringes. The contract has a completion date of January 23, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,097.53 firm-fixed price delivery order is for the supply of 4566293391 FULVESTRANT 250 MG/5 ML SYRING 5ML, a specialty pharmaceutical product, with an ultimate completion date of November 1, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Fulphila 6 mg/0.6 mL syringes with a ceiling value of $14,031.60 under firm fixed-price terms. The contract, which is not set-aside and was competitively awarded, calls for performance in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order represents a child contract issued under...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT904Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,928.60 to AmerisourceBergen Drug Corp for Fulvestrant 250 mg/5 ml syringes on November 14, 2025, with completion targeted for November 17, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award under AmerisourceBergen's existing pharmaceutical supply contract vehicle with DLA. The product will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle extending through December 2026. The parent IDC enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. AmerisourceBergen's demonstrated capability to meet federal procurement requirements through open competition, combined with its substantial prime contract with DLA, positions it as a critical vendor for supporting Defense Health Agency and other federal healthcare systems' pharmaceutical needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 11/14/25 |